Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Taiho Pharmaceutical
Biotech
Cullinan, Taiho tout 6-month survival benefit in lung cancer
The addition of zipalertinib to platinum-based chemotherapy improved survival by six months in patients with EGFR exon 20 insertion mutation NSCLC.
Marissa Russo
Sep 13, 2026 9:45pm
Taiho and Cullinan secure lung cancer victory to challenge J&J
Aug 13, 2026 6:00am
Cardiff Oncology churns C-suite—Chutes & Ladders
Jan 30, 2026 8:30am
UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss
Jul 8, 2025 10:17am
ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC
May 22, 2025 5:00pm
Otsuka's Taiho pays $400M to buy Swiss ADC partner
Mar 17, 2025 8:10am
